Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Newly Diagnosed Multiple Myeloma (NDMM) Trials Landscape
Newly diagnosed multiple myeloma (NDMM) represents the most critical therapeutic window for achieving initial deep MRD negativity. Active trials in China focus on quadruplet induction regimens and early frontline cell therapy integrations.
As of 2026-10-21, there are 4 active interventional trials dedicated to this patient population in China.
Clinical Characteristics & Guidance
For transplant-eligible patients, frontline clinical trials aim for deep MRD negativity; for transplant-ineligible elderly patients, the focus is optimal efficacy with balanced tolerability.
Enrollment must typically be evaluated before starting systematic first-line chemotherapy to prevent prior exposure exclusions.
Participants receive specialized monitoring at top-tier hematology centers with investigational drugs and study-related tests covered by sponsors.
Active Studies (4)
Population synthesized by CMDNShowing 4 published English records of 4 registry trials.